UBS, Guggenheim Trim Rapport Price Targets After Q3 as Shares Rebound
UBS and Guggenheim cut their price targets on Rapport after its third-quarter report but kept Buy ratings, and Wells Fargo held Overweight. The stock fell 8.52% on Thursday, before the notes, then rose 3.04% on Friday.

UBS and Guggenheim lowered their price targets on Rapport Therapeutics, Inc. (NASDAQ: RAPP) on Nov. 5, after the company's third-quarter 2026 results. The first note appeared at 5:32 p.m. ET, after the close. UBS kept Buy and cut its target to $64 from $71, and Guggenheim kept Buy and cut to $66 from $70.
Lower targets, unchanged ratings
Wells Fargo also kept Overweight, with a $47 target. None of the three firms changed a rating, and every target sits well above the $24.44 close on Nov. 6, with Wells Fargo's the lowest. WSN takes no side on the ratings.
The drop came first, the rebound followed
Thursday's 8.52% fall was not a reaction to these notes. Shares closed at $23.72 on Nov. 5, and the first note came after the close. In after-hours trading (the session after 4:00 p.m. ET) that evening, shares fell a further 2.57%.
Friday's pre-market session (before 9:30 a.m. ET) was nearly empty, with 3,719 shares traded. At 9:28 a.m. ET shares were at $23.39, 1.39% below Thursday's close. In the regular session the stock traded between $22.95 and $24.53 and closed at $24.44, up 3.04% from Thursday. After-hours trading on Nov. 6 was flat at $24.44 on 42,342 shares.
The longer path is down. From Oct. 8 through Nov. 5 the stock lost 20.54%, after peaking at $31.31 on Oct. 20. It fell 18.3% on Oct. 28, its worst day of the period. That day the company priced public offerings of common stock and convertible notes, according to its pricing release. Shares closed at $25.05 on Oct. 30, rose to $25.93 on Nov. 4 and gave back most of that on Nov. 5.
Friday's gain came on light volume
Volume in the regular session was 648,722 shares, about half the 10-day average of 1,673,103. The float, the shares available to trade, is 45.07 million, so Friday's volume was about 1.4% of it. The company's market value is about $1.17 billion.
Cuts of $4 to $7 per share, with Buy ratings intact, did not come with a heavy-volume reaction.
What to watch next
- Rapport said on Nov. 3 that it will take part in upcoming investor conferences.
Bottom line
Three firms kept positive ratings after the quarter, two with lower targets. The stock's 8.52% drop came before the notes, and its 3.04% gain on Friday came on volume well under average.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




